Multimodal MR imaging of brain iron in attention deficit hyperactivity disorder: A noninvasive biomarker that responds to psychostimulant treatment?

Radiology

Volumn 272, Issue 2, 2014, Pages 524-532

  Adisetiyo, Vitria ^a   Jensen, Jens H ^a   Tabesh, Ali ^a   Deardorff, Rachael L ^a   Fieremans, Els ^b   Di Martino, Adriana ^b   Gray, Kevin M ^a   Castellanos, Francisco X ^b,c   Helpern, Joseph A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; ESCITALOPRAM; IRON; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; SERTRALINE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN LEVEL; CAUDATE NUCLEUS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RESPONSE; FEMALE; GLOBUS PALLIDUS; HUMAN; IRON BLOOD LEVEL; MALE; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUTAMEN; THALAMUS;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOLOGICAL MARKERS; BRAIN MAPPING; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; ECHO-PLANAR IMAGING; FEMALE; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; PROSPECTIVE STUDIES;

EID: 84905044179     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14140047     Document Type: Article

References (40)

1. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(11):1410-1415. (Pubitemid 40798562)
2. Swanson JM, Kinsbourne M, Nigg J, et al. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 2007;17(1):39-59. (Pubitemid 46355008)
3. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry 2012;169(3):264-272.
4. Swanson J, Baler RD, Volkow ND. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology 2011;36(1):207-226.
5. Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009;302(10):1084-1091.
6. Mohamed WM, Unger EL, Kambhampati SK, Jones BC. Methylphenidate improves cognitive deficits produced by infantile iron deficiency in rats. Behav Brain Res 2011;216(1):146-152.
7. Cortese S, Azoulay R, Castellanos FX, et al. Brain iron levels in attention-deficit/hyperactivity disorder: a pilot MRI study. World J Biol Psychiatry 2012;13(3):223-231.
8. Cortese S, Angriman M, Lecendreux M, Konofal E. Iron and attention deficit/hyperactivity disorder: what is the empirical evidence so far? A systematic review of the literature. Expert Rev Neurother 2012;12(10):1227-1240.
9. Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 2011;508(1):1-12.
10. Ramsey AJ, Hillas PJ, Fitzpatrick PF. Characterization of the active site iron in tyrosine hydroxylase: redox states of the iron. J Biol Chem 1996;271(40):24395-24400.
11. Beard JL, Connor JR. Iron status and neural functioning. Annu Rev Nutr 2003;23:41-58. (Pubitemid 37059715)
12. McCann JC, Ames BN. An overview of evidence for a causal relation between iron deficiency during development and deficits in cognitive or behavioral function. Am J Clin Nutr 2007;85(4):931-945. (Pubitemid 46557905)
13. Lozoff B. Early iron deficiency has brain and behavior effects consistent with dopaminergic dysfunction. J Nutr 2011;141(4):740S-746S.
14. Dusek P, Dezortova M, Wuerfel J. Imaging of iron. Int Rev Neurobiol 2013;110:195-239.
15. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005;23(1):1-25. (Pubitemid 40269946)
16. Jensen JH, Chandra R, Ramani A, et al. Magnetic field correlation imaging. Magn Reson Med 2006;55(6):1350-1361. (Pubitemid 43856773)
17. Jensen JH, Szulc K, Hu C, et al. Magnetic field correlation as a measure of iron-generated magnetic field inhomogeneities in the brain. Magn Reson Med 2009;61(2):481-485.
18. Adisetiyo V, Jensen JH, Ramani A, et al. In vivo assessment of age-related brain iron differences by magnetic field correlation imaging. J Magn Reson Imaging 2012;36(2):322-331.
19. Raz E, Jensen JH, Ge Y, et al. Brain iron quantification in mild traumatic brain injury: a magnetic field correlation study. AJNR Am J Neuroradiol 2011;32(10):1851-1856.
20. Dumas EM, Versluis MJ, van den Bogaard SJ, et al. Elevated brain iron is independent from atrophy in Huntington's disease. Neuroimage 2012;61(3):558-564.
21. Ge Y, Jensen JH, Lu H, et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007;28(9):1639-1644. (Pubitemid 47598131)
22. Wechsler D. Wechsler abbreviated scale of intelligence (WASI-II). San Antonio, Tex: Psychological Corporation, 1999.
23. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971;9(1):97-113.
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Arlington, Va: American Psychiatric Association, 2000.
25. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N. Diagnostic interview: Kiddie-Sadspresent and lifetime version (K-SADS-PL) - screen interview. University of Pittsburgh Department of Psychiatry Web site. http://psychiatry. pitt.edu/node/8233. Published October 1996. Accessed June 2006.
26. Conners CK. Conners rating scales-revised: technical manual. North Tonawanda, NY: Multi-Health Systems, 1997.
27. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function. Child Neuropsychol 2000;6(3):235-238.
28. Kim D, Jensen JH, Wu EX, Sheth SS, Brittenham GM. Breathhold multiecho fast spin-echo pulse sequence for accurate R2 measurement in the heart and liver. Magn Reson Med 2009;62(2):300-306.
29. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958;3(1):41-51.
30. Ardekani BA, Guckemus S, Bachman A, Hoptman MJ, Wojtaszek M, Nierenberg J. Quantitative comparison of algorithms for inter-subject registration of 3D volumetric brain MRI scans. J Neurosci Methods 2005;142(1):67-76. (Pubitemid 40138029)
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57(1):289-300.
32. Engert V, Pruessner JC. Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Curr Neuropharmacol 2008;6(4):322-328.
33. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011;69(12):e145-e157.
34. Del Campo N, Müller U, Sahakian BJ. Neural and behavioral endophenotypes in ADHD. Curr Top Behav Neurosci 2012;11:65-91.
35. Egerton A, Mehta MA, Montgomery AJ, et al. The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev 2009;33(7):1109-1132.
36. Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord 2007;22(Suppl 18):S440-S448.
37. Rizzo G, Tonon C, Manners D, Testa C, Lodi R. Imaging brain functional and metabolic changes in restless legs syndrome. Curr Neurol Neurosci Rep 2013;13(9):372-378.
38. Connor JR, Wang XS, Allen RP, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 2009;132(Pt 9):2403-2412.
39. Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann N Y Acad Sci 2010;1187:316-340.
40. Donfrancesco R, Parisi P, Vanacore N, Martines F, Sargentini V, Cortese S. Iron and ADHD: time to move beyond serum ferritin levels. J Atten Disord 2013;17(4):347-357.